Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
179.38
-3.72 (-2.03%)
At close: Sep 18, 2026, 4:00 PM EDT
183.50
+4.12 (2.30%)
After-hours: Sep 18, 2026, 7:34 PM EDT
Guardant Health Revenue
Guardant Health had revenue of $334.98M in the quarter ending June 30, 2026, with 44.33% growth. This brings the company's revenue in the last twelve months to $1.18B, up 42.74% year-over-year. In the year 2025, Guardant Health had annual revenue of $982.02M with 32.88% growth.
Revenue (ttm)
$1.18B
Revenue Growth
+42.74%
P/S Ratio
20.35
Revenue / Employee
$472,109
Employees
2,506
Market Cap
24.07B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 982.02M | 243.01M | 32.88% |
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% |
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
| Dec 31, 2020 | 286.73M | 72.36M | 33.75% |
| Dec 31, 2019 | 214.38M | 123.74M | 136.52% |
| Dec 31, 2018 | 90.64M | 40.80M | 81.85% |
| Dec 31, 2017 | 49.84M | 24.59M | 97.40% |
| Dec 31, 2016 | 25.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Labcorp Holdings | 14.35B |
| Quest Diagnostics | 11.56B |
| ICON Public Limited Company | 8.29B |
| Agilent Technologies | 7.37B |
| Waters | 4.64B |
| IDEXX Laboratories | 4.55B |
| Illumina | 4.49B |
| Mettler-Toledo International | 4.13B |
GH News
- 4 days ago - Guardant Health Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 5 days ago - Guardant Health's Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening - Business Wire
- 10 days ago - Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer - Business Wire
- 10 days ago - Guardant Health assumed with a Buy at UBS - TheFly
- 11 days ago - Business Insider Names Guardant Health One of America's Most Innovative Businesses - Business Wire
- 11 days ago - Guardant Health initiated with a Buy at Rothschild & Co Redburn - TheFly
- 15 days ago - Guardant announces FDA approval of Guardant360 CDx as companion diagnostic - TheFly
- 15 days ago - Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced Breast Cancer - Business Wire